Ferretti debuts at Piazza Affari on June 27, Iervolino as anchor investor
26 juin 2023 08h52 HE
|
Ferretti
MILAN, Italy, June 26, 2023 (GLOBE NEWSWIRE) -- Ferretti's luxury yachts are just one step away from Piazza Affari. The Group, currently listed on the Hong Kong Stock Exchange, announced the...
Hairmax Appoints Ryan F. Zackon as Chief Executive Officer
14 juin 2023 08h59 HE
|
Hairmax
BOCA RATON, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- Hairmax, the pioneer and global leader in transformative hair regrowth, announced today that it has appointed Ryan F. Zackon as its Chief...
Skyward Specialty Announces Closing of Secondary Offering of its Common Stock
12 juin 2023 13h56 HE
|
Skyward Specialty Insurance Group, Inc.
HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc.TM (NASDAQ: SKWD) ("Skyward Specialty" or the “Company"), a leader in the specialty property and casualty...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
07 juin 2023 08h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Skyward Specialty Announces Secondary Offering of Its Common Stock
05 juin 2023 16h59 HE
|
Skyward Specialty Insurance Group, Inc.
HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc.TM (NASDAQ: SKWD) ("Skyward Specialty" or the "Company"), a leader in the specialty property and casualty...
Structure Therapeutics to Present at Jefferies Healthcare Conference
31 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
25 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
18 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
IX Acquisition Corp. Announces Second Extension of Deadline to Complete Initial Business Combination
09 mai 2023 20h05 HE
|
IX Acquisition Corp.
NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- IX Acquisition Corp. (NASDAQ: IXAQU, IXAQA, IXAQUW) (“IXAQ” or the “Company”), announced today that its board of directors (the “Board”) has decided to...